NICE backs Forxiga for type 1 diabetes patients

12 July 2019

Medicines cost-effectiveness watchdog the National Institute for Health and Care Excellence (NICE) has issued a positive Final Appraisal Determination (FAD) for Forxiga (dapagliflozin) 5mg with insulin as an option for treating type 1 diabetes in England and Wales.

AstraZeneca (LSE: AZN), the drug’s marketer, says Forxiga is cleared for adults with a body mass index (BMI), of at least 27kg/m2, when insulin alone does not provide adequate glycemic control despite optimal insulin therapy, only if:

they are on insulin doses of more than 0.5 units/kg of body weight/day and
they have completed a structured education program that includes information about:

the risk of diabetic ketoacidosis
how to recognize risk factors for diabetic ketoacidosis, and its signs and symptoms
how and when to monitor blood ketone levels
what actions to take for elevated blood ketones, and

treatment is started and supervised in a hospital diabetes clinic.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK